Long‐term efficacy of miglustat in paediatric patients with Niemann‐Pick disease type C
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Niemann‐Pick disease type C (NP‐C) is a rare inherited neurovisceral disease characterized by progressive neurological manifestations. Oral miglustat was first approved for the treatment of children and adults with NP‐C in Europe in 2009. There are still relatively few published data on the long‐term efficacy and safety of miglustat in patients with NP‐C in clinical practice. We report the effects of up to 6 years of treatment with miglustat 100 mg t.i.d. in five children. Overall, 3/5 patients displayed progressive dysphagia before starting miglustat, and 4/5 showed marked cognitive and/or motor impairment. The mean age at treatment start was 11.6 years, and the median (range) duration of therapy so far is 4 (4.1 to 6.1) years. No treatment dose alterations were required, but therapy was interrupted for 1–3 months at least once in all patients due to supply issues. Swallowing function was stabilised during miglustat therapy, with no significant increase in Han dysphagia scale or aspiration‐penetration index scores among four evaluable patients (p > 0.05). Scores on the mini‐mental state examination indicated an improvement in cognitive function during the first 3–6 months of miglustat therapy, followed by stabilisation up to 5 years. Ambulatory function remained stable for at least the first 2 years of treatment in most patients, but there was a trend towards deterioration thereafter, possibly related to treatment interruptions. The safety/tolerability profile of miglustat was similar to previous clinical studies, although reports of gastrointestinal disturbances were rare. Overall, miglustat appeared to stabilise key parameters of neurological disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A penetration-aspiration scale
Rosenbek, J. C., Robbins, J. A., Roecker, E. B., Coyle, J. L., & Wood, J. L. (1996) · Dysphagia · doi:10.1007/bf00417897 · Cited by 2,803
Vanier, M. T. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-16 · Cited by 1,222
Cited by
Sphingolipid lysosomal storage disorders
Platt, F. M. (2014) · Nature · doi:10.1038/nature13476 · Cited by 320
Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders
Coutinho, M., Santos, J., & Alves, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071065 · Cited by 116
Relative acidic compartment volume as a lysosomal storage disorder–associated biomarker
te Vruchte, D., Speak, A. O., Wallom, K. L., Al Eisa, N., Smith, D. A., Hendriksz, C. J., Simmons, L., Lachmann, R. H., Cousins, A., Hartung, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72835 · Cited by 73
Li, R., Hao, J., Fujiwara, H., Xu, M., Yang, S., Dai, S., Long, Y., Swaroop, M., Li, C., Vu, M., et al. (2017) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2017.774 · Cited by 21
Du, K., Chen, H., Pan, Z., Zhao, M., Cheng, S., Luo, Y., Zhang, W., & Li, D. (2025) · eLife · doi:10.7554/elife.103137 · Cited by 13
Metadata
- Authors
- Chien, Y. H., Peng, S. F., Yang, C. C., Lee, N. C., Tsai, L. K., Huang, A. C., Su, S. C., Tseng, C. C., & Hwu, W. L.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2012-04-05
- Volume
- 36
- Issue
- 1
- Pages
- 129-137
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2043965507
- Cited by
- 41
- References
- 2
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term efficacy of miglustat in paediatric patients with Niemann‐Pick disease type C. https://app.cochat.ai/papers/10.1007/s10545-012-9479-9
- The paper
- Chien, Y. H., Peng, S. F., Yang, C. C., Lee, N. C., Tsai, L. K., Huang, A. C., Su, S. C., Tseng, C. C., & Hwu, W. L. (2013). Long‐term efficacy of miglustat in paediatric patients with Niemann‐Pick disease type C. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-012-9479-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.